CASE COMMENTS: MERGERS – EU – HORIZONTAL EFFECTS – COMMITMENTS

Phase II: The European Commission approves a concentration in the orthopedic implants sector subject to commitments in order to remedy the identified risks of horizontal effects on certain national markets, in particular since the parties are close competitors (Zimmer / Biomet)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. The European Commission published on February 25, 2016 a Phase II decision approving Zimmer's acquisition of its competitor Biomet. Both companies are both active in the European Economic Area countries in various markets for the production and marketing of orthopaedic prostheses (in particular for the knee, elbow, shoulder or hip) as well as, on a more ancillary basis, related surgical products. This decision may call for two sets of remarks, on procedure and substance. Procedural considerations In general, the European Commission appeared to be extremely vigilant on the quality of the information provided by the parties and, in particular, on their

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Olivier Billard, Guillaume Fabre, Phase II: The European Commission approves a concentration in the orthopedic implants sector subject to commitments in order to remedy the identified risks of horizontal effects on certain national markets, in particular since the parties are close competitors (Zimmer / Biomet), 30 March 2015, Concurrences N° 2-2016, Art. N° 79257, pp. 135-139

Visites 1895

All reviews